secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0001847903-24-000069
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for Centessa's ORX750 Phase 1 trial in narcolepsy; PoC data expected 2H 2024
--------------------------------------------------------------------------------

- FDA cleared IND for ORX750, an oral OX2R agonist targeting narcolepsy type 1 (NT1), NT2, and idiopathic hypersomnia.
- Phase 1 study includes SAD, MAD, and cross-over PoC using Maintenance of Wakefulness Test and Karolinska Sleepiness Scale in sleep-deprived healthy volunteers.
- FDA-set maximum exposure limit significantly exceeds predicted efficacious doses; no impact on planned development.
- Dosing to begin imminently; proof-of-concept data anticipated in second half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000069/0001847903-24-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000069/cnta-20240422.htm
  HTML page:      https://secwatch.observer/filing/0001847903-24-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer